• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immutep Ltd ADR (NQ: IMMP )

    2.630 -0.030 (-1.13%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 155,190
    Open 2.700
    Bid (Size) 2.520 (1)
    Ask (Size) 2.870 (2)
    Prev. Close 2.660
    Today's Range 2.600 - 2.720
    52wk Range 1.580 - 3.335
    Shares Outstanding 748,152,935
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
    Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024. 
    Via Benzinga

    Performance

    YTD
    +11.91%
    +11.91%
    1 Month
    -7.72%
    -7.72%
    3 Month
    +5.20%
    +5.20%
    6 Month
    +11.91%
    +11.91%
    1 Year
    +36.27%
    +36.27%

    More News

    Read More
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
    From Immutep Limited
    Via GlobeNewswire
    Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
    Via Benzinga
    Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting
    Via Benzinga
    Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know
    Via Benzinga
    Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
    From Immutep Limited
    Via GlobeNewswire
    Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
    From Immutep Limited
    Via GlobeNewswire
    7 Stocks That Could Triple Your Money by 2024
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
    Via Benzinga
    3 Best Penny Stocks Under $3 to Buy in June
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
    From Immutep Limited
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
    From Immutep Limited
    Via GlobeNewswire
    7 Best Penny Stocks Under $3 to Buy in April
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Why Did Immutep Ltd Stock Soar Recently?
    Via MarketBeat
    Topics Initial Public Offering
    Exposures Product Safety Securities Market
    Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
    From Immutep Limited
    Via GlobeNewswire
    Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
    From Immutep Limited
    Via GlobeNewswire
    Why AeroClean Technologies Is Trading Higher By Over 39%; Here Are 26 Stocks Moving Premarket
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.